Pub Date : 2023-02-09DOI: 10.4274/mjima.galenos.2023.2022.4
Bahise Çağla Taşkın Dalgıç, G. Yenişehirli, E. Tanrıverdi, A. Alici, B. Otlu
Introduction: The transmission rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by blood transfusion is thought to be low;however, it has not yet been proven whether the virus is transmitted by blood transfusion. Published studies have reported that SARS-CoV-2 RNA has been detected in the blood, plasma, or serum of infected individuals. This study aimed to investigate the presence of SARS-CoV-2 RNA in the serum of blood donors and evaluate the risk of transmission of SARS-CoV-2 by transfusion. Materials and Methods: In this study, 200 blood samples were taken from volunteer blood donors. In all serum samples, SARS-CoV-2 RNA was detected by reverse-transcription quantitative polymerase chain reaction assay. Medical records of the donors and recipients were retrospectively reviewed. Results: SARS-CoV-2 RNA was detected in seven (3.5%) of the donor serum samples. None of the positive donors had symptoms of coronavirus disease 2019 (COVID-19), and none had been admitted to the hospital after donation. Seven SARS-CoV-2 RNA-positive donor blood components were given to 12 recipients. No medical records indicated that COVID-19 occurred after the transfusion of blood components for recipients. Conclusion: This study demonstrated the presence of SARS-CoV-2 RNA in the serum of asymptomatic donors. Although our data suggest that the transfusion of blood products from asymptomatic donors to recipients with SARS-CoV-2 RNA in their serum may not result in COVID-19, further studies are needed to prove that SARS-CoV-2 is not transmitted by blood transfusion.
{"title":"Detection of SARS-CoV-2 RNA from the Serum Samples of Healthy Blood Donors","authors":"Bahise Çağla Taşkın Dalgıç, G. Yenişehirli, E. Tanrıverdi, A. Alici, B. Otlu","doi":"10.4274/mjima.galenos.2023.2022.4","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2023.2022.4","url":null,"abstract":"Introduction: The transmission rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by blood transfusion is thought to be low;however, it has not yet been proven whether the virus is transmitted by blood transfusion. Published studies have reported that SARS-CoV-2 RNA has been detected in the blood, plasma, or serum of infected individuals. This study aimed to investigate the presence of SARS-CoV-2 RNA in the serum of blood donors and evaluate the risk of transmission of SARS-CoV-2 by transfusion. Materials and Methods: In this study, 200 blood samples were taken from volunteer blood donors. In all serum samples, SARS-CoV-2 RNA was detected by reverse-transcription quantitative polymerase chain reaction assay. Medical records of the donors and recipients were retrospectively reviewed. Results: SARS-CoV-2 RNA was detected in seven (3.5%) of the donor serum samples. None of the positive donors had symptoms of coronavirus disease 2019 (COVID-19), and none had been admitted to the hospital after donation. Seven SARS-CoV-2 RNA-positive donor blood components were given to 12 recipients. No medical records indicated that COVID-19 occurred after the transfusion of blood components for recipients. Conclusion: This study demonstrated the presence of SARS-CoV-2 RNA in the serum of asymptomatic donors. Although our data suggest that the transfusion of blood products from asymptomatic donors to recipients with SARS-CoV-2 RNA in their serum may not result in COVID-19, further studies are needed to prove that SARS-CoV-2 is not transmitted by blood transfusion.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"49 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76945853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-07DOI: 10.4274/mjima.galenos.2023.2022.1
B. Halaçlı, Gulay Tok, Mehmet Yildirim, I. T. Geldigitti, Ebru Ortaç Ersoy, A. Topeli
Introduction: Dexamethasone is the first medication that improved survival in patients with Coronavirus disease-2019 (COVID-19);however, the effects of corticosteroids with different cumulative doses on disease outcome must be elucidated. Our study aimed to compare clinical features, hospital mortality, and secondary infections in patients with COVID-19 receiving different cumulative doses of systemic corticosteroids.Materials and Methods: A retrospective, observational study was conducted on patients with COVID-19 admitted to intensive care unit between 21st March 2020 and 20th September 2020 to determine who did not receive systemic corticosteroids, who received low-to-moderate cumulative doses of corticosteroids as recommended by the RECOVERY trial [proposed 6 mg of dexamethasone (equivalent to 32 mg methylprednisolone)] for 10 days (total dose of <= 320 mg of methylprednisolone or equivalent doses of corticosteroids), and who received high cumulative doses of corticosteroids (total dose of >320 mg methylprednisolone equivalent).Results: Among 134 patients, 35 (26%) did not receive systemic corticosteroids, 34 (25%) received low-to-moderate cumulative doses of corticosteroids, and 65 (49%) received high cumulative doses of corticosteroids. Secondary bacterial (31.4% vs. 41.2% and 63.1%, p=0.006) and opportunistic infections (2.9% vs. 5.9% and 21.5%, p=0.011) were more frequently observed in the low-to-moderate-and high-dose corticosteroid groups compared with those in the no corticosteroid group. Hospital mortality was 20% in patients who did not receive steroids and 29.4% and 46.2% in patients who received low-to-moderate and high doses of corticosteroids, respectively (p=0.012). High cumulative doses of systemic corticosteroids were found to be the independent determinant for hospital mortality [Odds ratio (OR): 6.302 (1.856-21.394);p=0.003] and secondary infection [OR: 3.334 (1.313-8.496);p=0.011].Conclusion: Comparison among patients administered with and without systemic corticosteroids revealed that high cumulative doses may be associated with adverse events in critically ill patients with COVID-19.
{"title":"Comparison of Cumulative Corticosteroid Doses in Critically-ill COVID-19 Patients","authors":"B. Halaçlı, Gulay Tok, Mehmet Yildirim, I. T. Geldigitti, Ebru Ortaç Ersoy, A. Topeli","doi":"10.4274/mjima.galenos.2023.2022.1","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2023.2022.1","url":null,"abstract":"Introduction: Dexamethasone is the first medication that improved survival in patients with Coronavirus disease-2019 (COVID-19);however, the effects of corticosteroids with different cumulative doses on disease outcome must be elucidated. Our study aimed to compare clinical features, hospital mortality, and secondary infections in patients with COVID-19 receiving different cumulative doses of systemic corticosteroids.Materials and Methods: A retrospective, observational study was conducted on patients with COVID-19 admitted to intensive care unit between 21st March 2020 and 20th September 2020 to determine who did not receive systemic corticosteroids, who received low-to-moderate cumulative doses of corticosteroids as recommended by the RECOVERY trial [proposed 6 mg of dexamethasone (equivalent to 32 mg methylprednisolone)] for 10 days (total dose of <= 320 mg of methylprednisolone or equivalent doses of corticosteroids), and who received high cumulative doses of corticosteroids (total dose of >320 mg methylprednisolone equivalent).Results: Among 134 patients, 35 (26%) did not receive systemic corticosteroids, 34 (25%) received low-to-moderate cumulative doses of corticosteroids, and 65 (49%) received high cumulative doses of corticosteroids. Secondary bacterial (31.4% vs. 41.2% and 63.1%, p=0.006) and opportunistic infections (2.9% vs. 5.9% and 21.5%, p=0.011) were more frequently observed in the low-to-moderate-and high-dose corticosteroid groups compared with those in the no corticosteroid group. Hospital mortality was 20% in patients who did not receive steroids and 29.4% and 46.2% in patients who received low-to-moderate and high doses of corticosteroids, respectively (p=0.012). High cumulative doses of systemic corticosteroids were found to be the independent determinant for hospital mortality [Odds ratio (OR): 6.302 (1.856-21.394);p=0.003] and secondary infection [OR: 3.334 (1.313-8.496);p=0.011].Conclusion: Comparison among patients administered with and without systemic corticosteroids revealed that high cumulative doses may be associated with adverse events in critically ill patients with COVID-19.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"42 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87482157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-07DOI: 10.4274/mjima.galenos.2023.2022.2
M. Çabalak, Tayibe Bal, E. Polat, S. Ocak, Y. Önlen
{"title":"Examination of the Reasons for Change in Treatment in Patients İnfected with Human Immunodeficiency Virus","authors":"M. Çabalak, Tayibe Bal, E. Polat, S. Ocak, Y. Önlen","doi":"10.4274/mjima.galenos.2023.2022.2","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2023.2022.2","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"109 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74747829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-13DOI: 10.4274/mjima.galenos.2022.2022.47
B. Ozdemir, E. Akıncı, A. But, S. Kazancioglu, A. C. Yastı, Y. N. Yüksek, İsa Sözen, H. Bodur
{"title":"Blood Stream Infections (BSI) in Severe Burn Patients: Epidemiology, Microbiology, Laboratory Features and Risk Factors for Mortality","authors":"B. Ozdemir, E. Akıncı, A. But, S. Kazancioglu, A. C. Yastı, Y. N. Yüksek, İsa Sözen, H. Bodur","doi":"10.4274/mjima.galenos.2022.2022.47","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.47","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"197 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75934595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-09DOI: 10.4274/mjima.galenos.2022.2022.44
Cansu Önlen Güneri, Pınar Döner Güner, Ö. Aslantaş
{"title":"Prevalence and Antibiotic-Resistant Profiles of Staphylococci Nasal Colonization in Nursing Home Residents","authors":"Cansu Önlen Güneri, Pınar Döner Güner, Ö. Aslantaş","doi":"10.4274/mjima.galenos.2022.2022.44","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.44","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"162 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73803766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-09DOI: 10.4274/mjima.galenos.2022.2022.46
D. Gökengin, O. Acet
{"title":"Switch to DTG+3TC in a Highly Treatment-Experienced Person Living with HIV","authors":"D. Gökengin, O. Acet","doi":"10.4274/mjima.galenos.2022.2022.46","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.46","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"28 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80283847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-02DOI: 10.4274/mjima.galenos.2022.2022.43
Deniz Yüce Yıldırım, A. Arı, Reyhan Yiş, Fahri Emrah Soylu, S. Tosun
{"title":"Comparison of the Efficacy of Colistin and Meropenem Monotherapy with Meropenem/Ertapenem Combination in an Experimental Sepsis Model of Carbapenemase-Producing Klebsiella Pneumoniae","authors":"Deniz Yüce Yıldırım, A. Arı, Reyhan Yiş, Fahri Emrah Soylu, S. Tosun","doi":"10.4274/mjima.galenos.2022.2022.43","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.43","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"42 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78208399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-02DOI: 10.4274/mjima.galenos.2022.2022.42
Esra Akkan Kuzucu, E. Çalışkan, Duygu Öcal, Z. Dansuk, M. Çağatay, Gülünar Erdem, A. Tekeli
{"title":"Investigation of Colistin Resistance and Heteroresistance in Acinetobacter spp. Isolates From Various Clinical Specimens","authors":"Esra Akkan Kuzucu, E. Çalışkan, Duygu Öcal, Z. Dansuk, M. Çağatay, Gülünar Erdem, A. Tekeli","doi":"10.4274/mjima.galenos.2022.2022.42","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2022.42","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"10 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75311266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：